Neutropenie als Nebenwirkung der Therapie mit hochdosierten intravenösen Immunglobulinen in der Dermatologie

Leitlinien empfehlen hochdosierte intravenöse Immunglobuline (IVIG) zur Behandlung therapierefraktärer kutaner Autoimmunerkrankungen. Für dermatologische Patienten liegen nur wenige Daten zu hämatologischen Nebenwirkungen dieser Therapie vor. In der vorliegenden Arbeit werden Inzidenz und klinische Folgen der IVIG‐induzierten Neutropenie untersucht.

[1]  D. Zillikens,et al.  S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[2]  T. Dainichi,et al.  Efficacy of intravenous immunoglobulins for laryngopharyngeal lesions and upper airway obstruction in epidermolysis bullosa acquisita , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  K. Sullivan,et al.  High‐dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft‐versus‐host disease , 2019, The British journal of dermatology.

[4]  A. Enk,et al.  High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease , 2019, Front. Immunol..

[5]  C. Riccardi,et al.  How Glucocorticoids Affect the Neutrophil Life , 2018, International journal of molecular sciences.

[6]  Shayna L Gordon,et al.  Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. , 2018, The Journal of investigative dermatology.

[7]  F. Galimberti,et al.  Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis , 2018, Clinical and experimental dermatology.

[8]  H. Pehamberger,et al.  Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  I. Gunnarsson,et al.  Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL , 2018, Lupus.

[10]  I. Gunnarsson,et al.  PS7:134 Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of baff and april , 2018 .

[11]  Chen Li,et al.  Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study , 2018, BMC Pediatrics.

[12]  A. Mostaghimi,et al.  Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series , 2018, The British journal of dermatology.

[13]  A. Enk,et al.  High‐dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[14]  M. Mustapa,et al.  British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017 , 2017, The British journal of dermatology.

[15]  A. R. Rätz Bravo,et al.  Leucopenia associated with metamizole: a case-control study. , 2017, Swiss medical weekly.

[16]  Y. Yamaguchi,et al.  A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. , 2017, Journal of dermatological science.

[17]  A. Enk,et al.  European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[18]  L. French,et al.  European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  B. Getta,et al.  Intravenous immunoglobulin induces short‐term reversal of drug‐induced autoimmune neutropenia , 2015, Transfusion medicine.

[20]  K. Hanschmann,et al.  The role of isoagglutinins in intravenous immunoglobulin–related hemolysis , 2015, Transfusion.

[21]  D. Zillikens,et al.  Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  T. Kuijpers,et al.  On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events , 2015, Front. Immunol..

[23]  E. R. Stiehm,et al.  Adverse effects of human immunoglobulin therapy. , 2013, Transfusion medicine reviews.

[24]  M. Akhtari,et al.  Hematologic toxicities associated with intravenous immunoglobulin therapy. , 2011, International immunopharmacology.

[25]  M. Rimbert,et al.  Intravenous immunoglobulins for neonatal alloimmune neutropenia refractory to recombinant human granulocyte colony-stimulating factor. , 2011, American journal of perinatology.

[26]  H. Shimizu,et al.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.

[27]  R. Padmore,et al.  Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis , 2008, Transfusion.

[28]  S. Miescher,et al.  Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. , 2006, Blood.

[29]  S. Smith,et al.  Intravenous immunoglobulin-induced reversible neutropenia in a renal transplant patient. , 2005, Clinical nephrology.

[30]  L. Raffini,et al.  Neutropenia Following IVIG Therapy in Pediatric Patients With Immune-Mediated Thrombocytopenia , 2005, Journal of pediatric hematology/oncology.

[31]  M. Eguchi,et al.  Suppressive Effect of Intravenous Immunoglobulin on Peripheral Blood Neutrophil Count in Patients With Idiopathic Thrombocytopenic Purpura , 2005, Journal of pediatric hematology/oncology.

[32]  H. Simon,et al.  Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. , 2003, The Journal of allergy and clinical immunology.

[33]  T. Hashimoto,et al.  Neutropenia as a Complication of High-Dose Intravenous Immunoglobulin Therapy in Adult Patients With Neuroimmunologic Disorders , 2003, Clinical neuropharmacology.

[34]  M. Berkovitch,et al.  Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. , 1999, International journal of immunopharmacology.

[35]  Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. , 1999, MMWR. Morbidity and mortality weekly report.

[36]  M. Dalakas,et al.  Effect of high‐dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases , 1997, Muscle & nerve.

[37]  W. Peetermans,et al.  Aseptic Meningitis and Intravenous Immunoglobulin Therapy , 1995, Annals of Internal Medicine.

[38]  C. Scribner,et al.  Aseptic Meningitis and Intravenous Immunoglobulin Therapy , 1995, Annals of Internal Medicine.

[39]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[40]  S. Bertolone,et al.  Neonatal Immune Neutropenia Following the Administration of Intravenous Immune Globulin , 1993, The American journal of pediatric hematology/oncology.

[41]  M. Macey,et al.  Drug points: Neutropenia following intravenous immunoglobulin , 1988 .

[42]  M. Macey,et al.  Neutropenia following intravenous immunoglobulin. , 1988, British medical journal.

[43]  R. Majer,et al.  Drug points: Neutropenia caused by intravenous immunoglobulin , 1988 .

[44]  P. Green,et al.  Neutropenia caused by intravenous immunoglobulin. , 1988, British medical journal.

[45]  A. Burks,et al.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. , 1986, The New England journal of medicine.